Video

Workplace Wellness Can Help Reduce the Risk for Heart Problems

Some Parents May Hasten Death for Terminally Ill Children

Fitness Academics

Secondhand Smoke Increases Risk for Heart Disease in Kids

Toddlers Don't Learn Vocabulary From TV

Despite Worries, Most Parents Vaccinate Their Kids Anyway

Food Allergies Can Be Treated With the Allergen Foods

Signs of Heart Disease Could Be As Early as 3 in Obese Kids

The Number of Women Having Strokes is Rising

Preventative Mastectomy

Cases of Gestational Diabetes Are On the Rise

Nintendo Wii Could Be Therapy for Stroke Victims

Single Men Have An Increased Risk for Stroke

Fatty Foods Could Lead to Stroke in Older Women

Woman Gives Birth After Ovary Transplant

New Drug Could Work Against Leukemia

Posted on 07/02/2009, 12:00
By -- Robert Preidt

Researchers see promise for treatment of AML and other cancers

THURSDAY, July 2 (HealthDay News) -- A new targeted therapy shows promise in treating acute myeloid leukemia, a highly treatment-resistant blood cancer, according to a new study.

Researchers created an antibody (7G3) that recognizes and binds to a molecule called CD123, which is expressed at high levels on leukemia stem cells (LSCs), but not on normal blood cells. LSCs are cells that can cause acute myeloid leukemia (AML) and are critical for its long-term growth.

When AML-LSCs from human patients were transplanted into mice, those treated with 7G3 survived longer than mice that didn't receive the antibody. The researchers found that 7G3 blocked a signaling pathway in tumor cells, impaired migration of AML-LSCs to bone marrow and activated the immune system to destroy AML-LSCs.

The findings, published in the July 2 issue of the journal Cell Stem Cell, hold promise for future cancer treatments, according to the study authors.

"The recent characterization of defined populations of cancer stem cells in a range of human malignancies, as well as their relative resistance to conventional chemotherapy and radiotherapy, supports the broad applicability of our approach and provides rationale for the progression of AML-LSC-targeted therapeutics from preclinical evaluation to clinical trials," wrote Richard Lock, an associate professor at the Children's Cancer Institute Australia and the University of New South Wales, in a news release.

More information

To learn more about AML, visit the National Cancer Institute.

SOURCE: Cell Press, news release, July 2, 2009

More news in Cardio Health...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 3.1 / 5 (9 votes)